Isn't this the best possible news - that we don't need the patent because 2-73 is a miracle on it's own? Clearly there has been little pressure on the stock since the news came out. I'm frankly thrilled they put it in writing before the patent got rejected - one of the best nuggets buried within the PR. Looks like good planning with the investment community if you ask me.
That average return (following recommendations) for that FBR analyst might be ticking up soon.
Not necessarily. I expect them to continue to try and get the patent. The fact that they likely don't need Plus to be patented (due to 2-73) is of extreme benefit, but a patent on your drug combination is still a strategic thing to have.
News 
Market Data 
Discover 
